Ruzhi Zhang | Dermatopathology| Best Researcher Award
Dr. Ruzhi Zhang, The Second Affiliated Hospital of Wannan Medical College, China
Dr. Ruzhi Zhang is a distinguished medical researcher at Wannan Medical College in Wuhu, China. With a career spanning several years, Dr. Zhang has made significant contributions to dermatopathology and antibacterial research. His work integrates clinical practice with innovative scientific research, focusing on enhancing therapeutic strategies for skin conditions.
Publication Profile
Education and Experience
Dr. Zhang holds advanced degrees in medical sciences and has extensive experience working in various research and clinical settings. His academic journey has equipped him with a profound understanding of dermatology and related fields, enabling him to spearhead numerous impactful research projects.
Professional Development
Dr. Zhang continuously engages in professional development activities, including attending international conferences, publishing in high-impact journals, and collaborating with researchers worldwide. His dedication to lifelong learning ensures he remains at the forefront of medical research advancements.
Research Focus
Dr. Zhang’s research primarily focuses on dermatopathology, photodynamic therapy, and the development of novel antibacterial treatments. He is particularly interested in the application of imidazolium poly(ionic liquids) and acrylic nanoparticles for skin therapy, aiming to improve patient outcomes through cutting-edge technology.
Publications
- Lichen Planus Pemphigoides Induced by Camrelizumab in Combination with Lenvatinib (2024)
- In Vitro Antibacterial and Anti-Inflammatory Properties of Imidazolium Poly(ionic liquids) Microspheres Loaded in GelMA-PEG Hydrogels (2024)
- A patient with multiple asymptomatic yellow papules on the scalp (2024)
- Five percent 5-aminolevulinic acid photodynamic therapy for the treatment of dissecting cellulitis of the scalp (2024)
- Characterization of CM-Dil-labeled Muse cells in culture and in skin wounds in rats (2024)
- Corrigendum to “Hemoporfin-mediated photodynamic therapy for the treatment of port-wine stain: A multicenter, retrospective study” (2024)
- The inhibition of VDAC1 oligomerization promotes pigmentation through the CaMK–CRTCs/CREB–MITF pathway (2024)